Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 09:14, 22 April 2012 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 edits Fix ChEBI: this is about 17beta-estradiol← Previous edit		Latest revision as of 19:22, 28 November 2024 edit undo2600:6c55:4a00:f4a:81:b155:6d2e:caf8 (talk) →Neuropsychopharmacology: added product insert information contentTags: Mobile edit Mobile web edit
(649 intermediate revisions by more than 100 users not shown)
Line 1:		Line 1:
			{{About|estradiol as a hormone|its use as a medication|Estradiol (medication)}}
	{{Distinguish|17α-estradiol}}
			{{Use dmy dates|date=August 2018}}
	{{Drugbox
			{{Chembox
	| Verifiedfields = changed
			<!-- Images -->
	| verifiedrevid = 457463793
			| ImageFile1 = Estradiol.svg
	| IUPAC_name = (17β)-estra-1,3,5(10)-triene-3,17-diol
			| ImageSize1 = 225px
	| image = Estradiol.svg
			| ImageAlt1 = The chemical structure of estradiol.
	| width = 200
	| image2 = Oestradiol-3D-balls.png		| ImageFile2 = Estradiol 3D ball.png
			| ImageSize2 = 225px
			| ImageAlt2 = A ball-and-stick model of estradiol.
	<!--Clinical data-->
			<!-- Names -->
	| tradename = Climara, Menostar
			| pronounce = {{IPAc-en|ˌ|ɛ|s|t|r|ə|ˈ|d|aɪ|oʊ|l}} {{respell|ES|trə|DY|ohl}}<ref name="FordRoach2013" /><ref name="HochadelMosby2015" />
	| Drugs.com = {{drugs.com|monograph|estradiol}}
			| IUPACName = Estra-1,3,5(10)-triene-3,17β-diol
	| pregnancy_category = X (])
			| SystematicName = (1''S'',3a''S'',3b''R'',9b''S'',11a''S'')-11a-Methyl-2,3,3a,3b,4,5,9b,10,11,11a-decahydro-1''H''-cyclopentaphenanthrene-1,7-diol
	| legal_status = S4 <small>(Au)</small>, POM <small>(])</small>, ℞-only <small>(U.S.)</small>
			| OtherNames = Oestradiol; E2; 17β-Estradiol; 17β-Oestradiol
	| routes_of_administration = Oral, transdermal
			| Watchedfields = changed
			| verifiedrevid = 488623959
	<!--Pharmacokinetic data-->
			<!-- Sections -->
	| bioavailability = 97–99% is bound
			| Section1 = {{Chembox Identifiers
	| metabolism = ]
	| elimination_half-life = ~ 13 h
	| excretion = Urine, and sweat glands
	<!--Identifiers-->
	| CASNo_Ref = {{cascite|correct|CAS}}		| CASNo_Ref = {{cascite|correct|CAS}}
			| CASNo = 50-28-2
	| CAS_number_Ref = {{cascite|correct|??}}
			| ChEBI_Ref = {{ebicite|correct|EBI}}
	| CAS_number = 50-28-2
			| ChEBI = 16469
	| CAS_supplemental = <br/>57-91-0 (±) <!-- Also CAS verified -->
			| ChEMBL_Ref = {{ebicite|correct|EBI}}
	| ATC_prefix = G03
	| ATC_suffix = CA03		| ChEMBL = 135
			| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
	| PubChem = 5757
	| IUPHAR_ligand = 1012		| ChemSpiderID = 5554
	| DrugBank_Ref = {{drugbankcite|correct|drugbank}}		| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
	| DrugBank = DB00783		| DrugBank = DB00783
			| EINECS = 200-023-8
	| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
	| ChemSpiderID = 5554
	| UNII_Ref = {{fdacite|correct|FDA}}
	| UNII = 4TI98Z838E
	| KEGG_Ref = {{keggcite|correct|kegg}}		| KEGG_Ref = {{keggcite|correct|kegg}}
	| KEGG = D00105		| KEGG = D00105
			| PubChem = 5757
	| ChEBI_Ref = {{ebicite|changed|EBI}}
			| SMILES = C12CC3c4ccc(cc4CC31CC2O)O
	| ChEBI = 16469
	| ChEMBL_Ref = {{ebicite|correct|EBI}}
	| ChEMBL = 135
	<!--Chemical data-->
	| C=18 | H=24 | O=2
	| molecular_weight = 272.38
	| smiles = C12CC3c4ccc(cc4CC31CC2O)O
	| InChI = 1/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}		| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChI = 1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1		| StdInChI = 1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
	| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}		| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChIKey = VOXZDWNPVJITMN-ZBRFXRBCSA-N		| StdInChIKey = VOXZDWNPVJITMN-ZBRFXRBCSA-N
			| UNII_Ref = {{fdacite|correct|FDA}}
	| synonyms = <small>(8''R'',9''S'',13''S'',14''S'',17''S'')-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopentaphenanthrene-3,17-diol</small>
			| UNII = 4TI98Z838E
	}}
			}}
	'''Estradiol''' (E2 or 17β-estradiol, also '''oestradiol''') is a ]. Estradiol is abbreviated E2 as it has 2 ] groups in its molecular structure. ] has 1 (E1) and ] has 3 (E3). Estradiol is about 10 times as potent as estrone and about 80 times as potent as estriol in its estrogenic effect. Except during the early follicular phase of the ], its serum levels are somewhat higher than that of estrone during the reproductive years of the human female. Thus it is the predominant ] during reproductive years both in terms of absolute serum levels as well as in terms of estrogenic activity. During menopause, estrone is the predominant circulating ] and during pregnancy estriol is the predominant circulating ] in terms of serum levels. Estradiol is also present in males, being produced as an active metabolic product of ]. The serum levels of estradiol in males (14 - 55 pg/mL) are roughly comparable to those of ] women (< 35 pg/mL). Estradiol ''in vivo'' is interconvertible with estrone; estradiol to estrone conversion being favored. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs, including the bones.
			| Section2 = {{Chembox Properties
			| C=18 | H=24 | O=2
			| MolarMass = 272.38 g/mol
			| Appearance =
			| Density =
			| MeltingPt =
			| BoilingPt =
			| Solubility =
			| MagSus = -186.6·10<sup>−6</sup> cm<sup>3</sup>/mol
			}}
			| Section3 = {{Chembox Hazards
			| MainHazards =
			| FlashPt =
			| AutoignitionPt =
			}}
			| Section6 = {{Chembox Pharmacology
			| ATCvet =
			| ATCCode_prefix = G03
			| ATCCode_suffix = CA03
			| ATC_Supplemental =
			| Licence_EU=yes
			| AdminRoutes = ], ], ], ]/], ], ] or ] (as an ]), ]
			| Bioavail = Oral: <5%<ref name="StanczykArcher2013" />
			| Excretion = ]: 54%<ref name="StanczykArcher2013" /><br />]: 6%<ref name="StanczykArcher2013" />
			| HalfLife = Oral: 13–20 hours<ref name="StanczykArcher2013" /><br />Sublingual: 8–18 hours<ref name="PriceBlauer1997" /><br />Topical (gel): 36.5 hours<ref name="NauntonAl Hadithy2006" />
			| Metabolism = ] (via ], ], ])
			| ProteinBound = ~98%:<ref name="StanczykArcher2013" /><ref name="FalconeHurd2007" /><br />• ]: 60%<br />• {{abbr|SHBG|sex hormone-binding globulin}}: 38%<br />• Free: 2%
			}}
			}}
			'''Estradiol''' ('''E2'''), also called '''oestrogen''', '''oestradiol''', is an ] ] and the major ] ]. It is involved in the regulation of female ]s such as ] and ]s. Estradiol is responsible for the development of female ]s such as the ]s, ] and a ]. It is also important in the development and maintenance of female ]s such as the ]s, ] and ] during ], ] and ].<ref name="pmid7083198" /> It also has important effects in many other ]s including ], ], ], ], and the ].
	==Synthesis==
	]
	Estradiol, like other ]s, is derived from ]. After ] cleavage and using the delta-5 or the delta-4 pathway, ] is the key intermediary. A fraction of the ] is converted to ], which in turn undergoes conversion to estradiol by an enzyme called ]. In an alternative pathway, ] is ] to ], which is subsequently converted to estradiol.
			Though estradiol levels in males are much lower than in females, estradiol has important roles in males as well. Apart from humans and other ]s, estradiol is also found in most ]s and ]s, ]s, ], and other ] ].<ref name="Mechoulam_2005" /><ref name="Ozon_1972" />
	==Production==
	During the reproductive years, most estradiol in women is produced by the ]s of the ] by the aromatization of androstenedione (produced in the ] cells) to estrone, followed by conversion of ] to estradiol by ]. Smaller amounts of estradiol are also produced by the ], and (in men), by the ].
			Estradiol is produced within the ] of the ] and in other tissues including the ]s, the ]s, fat, ], the breasts, and the brain. Estradiol is ] from ] through a series of ]s and ]s.<ref>Saldanha, Colin J., Luke Remage-Healey, and Barney A. Schlinger. "Synaptocrine signaling: steroid synthesis and action at the synapse." Endocrine reviews 32.4 (2011): 532–549.</ref> The major ] involves the formation of ], which is then converted by ] into ] and is subsequently converted into estradiol. Alternatively, androstenedione can be converted into ], which can then be converted into estradiol. Upon ] in females, production of estrogens by the ovaries stops and estradiol levels decrease to very low levels.
	Estradiol is not produced in the gonads only: In both sexes, testosterone is converted by ] to estradiol. In particular, ] are active to convert precursors to estradiol, and will continue to do so even after menopause. Estradiol is also produced in the brain and in ]s.
			In addition to its role as a natural hormone, estradiol is used as a ], for instance in ] and ] for ]; for information on estradiol as a medication, see the ] article.
	==Mechanism of action==
	Estradiol enters cells freely and interacts with a cytoplasmic target ]. After the ] has bound its ], estradiol can enter the ] of the target cell, and regulate ], which leads to formation of ]. The mRNA interacts with ]s to produce specific proteins that express the effect of estradiol upon the target cell.
			{{TOC limit|3}}
	Estradiol binds well to both estrogen receptors, ERα, and ERβ, in contrast to certain other estrogens, notably medications that preferentially act on one of these receptors. These medications are called ]s, or SERMs.
			==Biological function==
	Estradiol is the most potent naturally occurring estrogen.
			===Sexual development===
	==Metabolism==
			{{See also|Breast development#Biochemistry}}
	In plasma, estradiol is largely bound to ], also to ]. Only a fraction of 2.21% (± 0.04%) is free and biologically active, the percentage remaining constant throughout the menstrual cycle.<ref>{{cite journal |author=Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G |title=Free and protein-bound plasma estradiol-17 beta during the menstrual cycle |journal=J. Clin. Endocrinol. Metab. |volume=43 |issue=2 |pages=436–45 |year=1976 |month=August |pmid=950372 |doi= 10.1210/jcem-43-2-436}}</ref> Deactivation includes conversion to less-active estrogens, such as ] and ]. Estriol is the major urinary metabolite. Estradiol is conjugated in the liver by sulfate and glucuronide formation and, as such, excreted via the kidneys. Some of the water-soluble conjugates are excreted via the bile duct, and partly reabsorbed after ] from the intestinal tract. This ] contributes to maintaining estradiol levels.
			The development of ] in women is driven by estrogens, to be specific, estradiol.<ref name="McMillanFeigin2006" /><ref name="CraigStitzel2004" /> These changes are initiated at the time of ], most are enhanced during the reproductive years, and become less pronounced with declining estradiol support after ]. Thus, estradiol produces ], and is responsible for changes in the ], affecting bones, joints, and ].<ref name="McMillanFeigin2006" /><ref name="CraigStitzel2004" /> In females, estradiol induces breast development, ], a ] (with fat deposited particularly in the breasts, hips, thighs, and buttocks), and maturation of the ] and ], whereas it mediates the ] (indirectly via increased ] secretion)<ref name="Preedy2011" /> and ] (thereby limiting ]) in both sexes.<ref name="McMillanFeigin2006" /><ref name="CraigStitzel2004" />
			===Reproduction===
			====Female reproductive system====
			In the female, estradiol acts as a growth hormone for tissue of the reproductive organs, supporting the lining of the ], the cervical glands, the ], and the lining of the fallopian tubes. It enhances growth of the ]. Estradiol appears necessary to maintain ]s in the ]. During the ], estradiol produced by the growing follicles triggers, via a positive feedback system, the hypothalamic-pituitary events that lead to the ] surge, inducing ovulation. In the luteal phase, estradiol, in conjunction with ], prepares the endometrium for ]. During ], estradiol increases due to ]l production. The effect of estradiol, together with ] and ], in ] is less clear. They may promote uterine blood flow, myometrial growth, stimulate breast growth and at term, promote cervical softening and expression of myometrial ] receptors.{{citation needed|date=February 2013}} In baboons, blocking of estrogen production leads to pregnancy loss, suggesting estradiol has a role in the maintenance of pregnancy. Research is investigating the role of estrogens in the process of initiation of ]. Actions of estradiol are required before the exposure of progesterone in the luteal phase.{{citation needed|date=February 2013}}
			====Male reproductive system====
			The effect of estradiol (and estrogens in general) upon male reproduction is complex. Estradiol is produced by action of ] mainly in the ]s of the ]ian ], but also by some ]s and the ]s of immature mammals.<ref>{{cite journal | vauthors = Carreau S, Lambard S, Delalande C, Denis-Galeraud I, Bilinska B, Bourguiba S | title = Aromatase expression and role of estrogens in male gonad : a review | journal = Reproductive Biology and Endocrinology | volume = 1 | pages = 35 | date = April 2003 | pmid = 12747806 | pmc = 155680 | doi = 10.1186/1477-7827-1-35 | doi-access = free }}</ref> It functions ('']'') to prevent ] of male ] cells.<ref>{{cite journal | vauthors = Pentikäinen V, Erkkilä K, Suomalainen L, Parvinen M, Dunkel L | title = Estradiol acts as a germ cell survival factor in the human testis in vitro | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 85 | issue = 5 | pages = 2057–67 | date = May 2000 | pmid = 10843196 | doi = 10.1210/jcem.85.5.6600 | doi-access = free }}</ref>
			While some studies in the early 1990s claimed a connection between globally declining ]s and estrogen exposure in the environment,<ref>{{cite journal | vauthors = Sharpe RM, Skakkebaek NE | title = Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? | journal = Lancet | volume = 341 | issue = 8857 | pages = 1392–5 | date = May 1993 | pmid = 8098802 | doi = 10.1016/0140-6736(93)90953-E | s2cid = 33135527 }}</ref> later studies found no such connection, nor evidence of a general decline in sperm counts.<ref>{{cite journal | vauthors = Handelsman DJ | title = Estrogens and falling sperm counts | journal = Reproduction, Fertility, and Development | volume = 13 | issue = 4 | pages = 317–24 | date = 2001 | pmid = 11800170 | doi=10.1071/rd00103}}</ref><ref>{{cite journal |vauthors=Fisch H, Goldstedin R |title=Environmental estrogens and sperm counts |journal=Pure and Applied Chemistry |date=2003 |volume=75 |issue=11–12 |pages=2181–2193 |url=http://pac.iupac.org/publications/pac/pdf/2003/pdf/7511x2181.pdf |doi=10.1351/pac200375112181 |s2cid=11068097 |access-date=29 December 2015 |archive-date=4 March 2016 |archive-url=https://web.archive.org/web/20160304102628/http://pac.iupac.org/publications/pac/pdf/2003/pdf/7511x2181.pdf |url-status=dead }}</ref>
			Suppression of estradiol production in a subpopulation of subfertile men may improve the ] analysis.<ref>{{cite journal | vauthors = Raman JD, Schlegel PN | title = Aromatase inhibitors for male infertility | journal = The Journal of Urology | volume = 167 | issue = 2 Pt 1 | pages = 624–9 | date = February 2002 | pmid = 11792932 | doi = 10.1016/S0022-5347(01)69099-2 }}</ref>
			Males with certain ] ]s, such as ], will have a higher level of estradiol.<ref>{{cite journal | vauthors = Visootsak J, Graham JM | title = Klinefelter syndrome and other sex chromosomal aneuploidies | journal = Orphanet Journal of Rare Diseases | volume = 1 | issue = 42 | pages = 42 | date = October 2006 | pmid = 17062147 | pmc = 1634840 | doi = 10.1186/1750-1172-1-42 | doi-access = free }}</ref>
			===Skeletal system===
			Estradiol has a profound effect on bone. Individuals without it (or other estrogens) will become tall and ]oid, as ] closure is delayed or may not take place.<ref>{{cite journal | vauthors = Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, Börjesson AE, Ohlsson C | display-authors = 6 | title = Sex steroid actions in male bone | journal = Endocrine Reviews | volume = 35 | issue = 6 | pages = 906–60 | date = December 2014 | pmid = 25202834 | pmc = 4234776 | doi = 10.1210/er.2014-1024 }}</ref> ] is also affected, resulting in early ] and ].<ref>{{cite journal | vauthors = Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER | display-authors = 6 | title = Effect of testosterone and estradiol in a man with aromatase deficiency | journal = The New England Journal of Medicine | volume = 337 | issue = 2 | pages = 91–5 | date = July 1997 | pmid = 9211678 | doi = 10.1056/NEJM199707103370204 | doi-access = free }}</ref> Low levels of estradiol may also predict fractures, with post-menopausal women having the highest incidence of ].<ref>{{cite journal | vauthors = Bergh C, Wennergren D, Möller M, Brisby H | title = Fracture incidence in adults in relation to age and gender: A study of 27,169 fractures in the Swedish Fracture Register in a well-defined catchment area | journal = PLOS ONE | volume = 15 | issue = 12 | pages = e0244291 | date = 2020-12-21 | pmid = 33347485 | pmc = 7751975 | doi = 10.1371/journal.pone.0244291 | bibcode = 2020PLoSO..1544291B | doi-access = free }}</ref> Women past menopause experience an accelerated loss of bone mass due to a relative estrogen deficiency.<ref>{{cite journal| vauthors = Albright F, Smith PH, Richardson AM |title=Postmenopausal Osteoporosis: Its Clinical Features|journal=]|author-link1 = Fuller Albright|date=31 May 1941 |volume=116 |issue=22 |pages=2465–2474 |doi=10.1001/jama.1941.02820220007002 }}</ref>
			===Skin health===
			The ], as well as the ], have been detected in the ], including in ]s and ]s.<ref name="pmid12762829">{{cite journal | vauthors = Raine-Fenning NJ, Brincat MP, Muscat-Baron Y | title = Skin aging and menopause : implications for treatment | journal = American Journal of Clinical Dermatology | volume = 4 | issue = 6 | pages = 371–8 | year = 2003 | pmid = 12762829 | doi = 10.2165/00128071-200304060-00001 | s2cid = 20392538 }}</ref><ref name="pmid16120154">{{cite journal | vauthors = Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB, Schmidt B | s2cid = 6077829 | title = Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study | journal = The British Journal of Dermatology | volume = 153 | issue = 3 | pages = 626–34 | date = September 2005 | pmid = 16120154 | doi = 10.1111/j.1365-2133.2005.06685.x }}</ref> At ] and thereafter, decreased levels of female ]s result in ], thinning, and increased ] of the skin and a reduction in skin ], firmness, and strength.<ref name="pmid12762829" /><ref name="pmid16120154" /> These skin changes constitute an acceleration in ] and are the result of decreased ] content, irregularities in the ] of ] ]s, decreased ] between ]s, and reduced ] and ].<ref name="pmid12762829" /><ref name="pmid16120154" /> The skin also becomes more ] during menopause, which is due to reduced skin ] and ] (sebum production).<ref name="pmid12762829" /> Along with chronological aging and photoaging, estrogen deficiency in menopause is one of the three main factors that predominantly influences skin aging.<ref name="pmid12762829" />
			] consisting of systemic treatment with estrogen alone or in combination with a progestogen, has well-documented and considerable beneficial effects on the skin of postmenopausal women.<ref name="pmid12762829" /><ref name="pmid16120154" /> These benefits include increased skin collagen content, skin thickness and elasticity, and skin hydration and surface lipids.<ref name="pmid12762829" /><ref name="pmid16120154" /> Topical estrogen has been found to have similar beneficial effects on the skin.<ref name="pmid12762829" /> In addition, a study has found that topical 2% progesterone cream significantly increases skin elasticity and firmness and observably decreases wrinkles in peri- and postmenopausal women.<ref name="pmid16120154" /> Skin hydration and surface lipids, on the other hand, did not significantly change with topical progesterone.<ref name="pmid16120154" /> These findings suggest that progesterone, like estrogen, also has beneficial effects on the skin, and may be independently protective against skin aging.<ref name="pmid16120154" />
			===Nervous system===
			{{further|Hypothalamic–pituitary–gonadal axis}}
			Estrogens can be produced in the ] from steroid precursors. As ], they have been found to have ] function.<ref>{{cite journal | vauthors = Behl C, Widmann M, Trapp T, Holsboer F | title = 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro | journal = Biochemical and Biophysical Research Communications | volume = 216 | issue = 2 | pages = 473–82 | date = November 1995 | pmid = 7488136 | doi = 10.1006/bbrc.1995.2647 }}</ref>
			The positive and negative ]s of the ] involve ovarian estradiol as the link to the hypothalamic-pituitary system to regulate ]s.<ref>{{cite journal | vauthors = Meethal SV, Liu T, Chan HW, Ginsburg E, Wilson AC, Gray DN, Bowen RL, Vonderhaar BK, Atwood CS | title = Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors | journal = Journal of Neurochemistry | volume = 110 | issue = 3 | pages = 1014–27 | date = August 2009 | pmid = 19493163 | pmc = 2789665 | doi = 10.1111/j.1471-4159.2009.06192.x }}</ref>
			Estrogen is considered to play a significant role in women's mental health, with links suggested between the hormone level, mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored.<ref>{{cite journal | vauthors = Douma SL, Husband C, O'Donnell ME, Barwin BN, Woodend AK | title = Estrogen-related mood disorders: reproductive life cycle factors | journal = Advances in Nursing Science | volume = 28 | issue = 4 | pages = 364–75 | year = 2005 | pmid = 16292022 | doi = 10.1097/00012272-200510000-00008 | s2cid = 9172877 }}</ref><ref>{{cite journal | vauthors = Lasiuk GC, Hegadoren KM | title = The effects of estradiol on central serotonergic systems and its relationship to mood in women | journal = Biological Research for Nursing | volume = 9 | issue = 2 | pages = 147–60 | date = October 2007 | pmid = 17909167 | doi = 10.1177/1099800407305600 | s2cid = 37965502 }}</ref>
			The volumes of ] brain structures in ] were found to change and approximate typical female brain structures when exposed to estrogen concomitantly with androgen deprivation over a period of months,<ref name="eje-utrecht">{{cite journal | vauthors = Hulshoff HE, Cohen-Kettenis PT, Van Haren NE, Peper JS, Brans RG, Cahn W, Schnack HG, Gooren LJ, Kahn RS | date = July 2006 | title = Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure | journal = European Journal of Endocrinology | volume = 155 | issue = suppl_1 | pages = 107–114 | doi = 10.1530/eje.1.02248 | doi-access = free }}</ref> suggesting that estrogen and/or androgens have a significant part to play in sex differentiation of the brain, both ]ly and later in life.
			There is also evidence the programming of adult male sexual behavior in many vertebrates is largely dependent on estradiol produced during prenatal life and early infancy.<ref>{{cite journal | vauthors = Harding CF | title = Hormonal modulation of singing: hormonal modulation of the songbird brain and singing behavior | journal = Annals of the New York Academy of Sciences | volume = 1016 | pages = 524–39 | date = June 2004 | issue = 1 | pmid = 15313793 | doi = 10.1196/annals.1298.030 | bibcode = 2004NYASA1016..524H | s2cid = 12457330 | url = http://www.annalsnyas.org/content/vol1016/issue1/index.dtl | archive-url = https://web.archive.org/web/20070927225947/http://www.annalsnyas.org/content/vol1016/issue1/index.dtl | url-status = dead | archive-date = 27 September 2007 }}</ref> It is not yet known whether this process plays a significant role in human sexual behavior, although evidence from other mammals tends to indicate a connection.<ref>{{cite journal | vauthors = Simerly RB | title = Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain | journal = Annual Review of Neuroscience | volume = 25 | pages = 507–36 | date = 27 March 2002 | pmid = 12052919 | doi = 10.1146/annurev.neuro.25.112701.142745 | url = http://www.healthsystem.virginia.edu/internet/neuroscience/BehavioralNeuroscience/Simerley-EFR-1-4.pdf | access-date = 7 March 2007 | archive-date = 1 October 2008 | archive-url = https://web.archive.org/web/20081001223447/http://www.healthsystem.virginia.edu/internet/neuroscience/BehavioralNeuroscience/Simerley-EFR-1-4.pdf | url-status = dead }}</ref>
			Estrogen has been found to increase the ] of oxytocin and to increase the ] of its ], the ], in the ].<ref name="GoldsteinMeston2005">{{cite book | vauthors = Goldstein I, Meston CM, Davis S, Traish A | title = Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment|url=https://books.google.com/books?id=3J7TnwpbZQwC&pg=PA205|date=17 November 2005|publisher=CRC Press|isbn=978-1-84214-263-9|pages=205–}}</ref> In women, a single dose of estradiol has been found to be sufficient to increase circulating oxytocin concentrations.<ref name="Acevedo-RodriguezMani2015">{{cite journal | vauthors = Acevedo-Rodriguez A, Mani SK, Handa RJ | title = Oxytocin and Estrogen Receptor β in the Brain: An Overview | journal = Frontiers in Endocrinology | volume = 6 | pages = 160 | year = 2015 | pmid = 26528239 | pmc = 4606117 | doi = 10.3389/fendo.2015.00160 | doi-access = free }}</ref>
			===Gynecological cancers===
			Estradiol has been tied to the development and progression of cancers such as breast cancer, ovarian cancer and endometrial cancer. Estradiol affects target tissues mainly by interacting with two ]s called ] (ERα) and ] (ERβ).<ref name=flav>{{cite journal | vauthors = Bulzomi P, Bolli A, Galluzzo P, Leone S, Acconcia F, Marino M | title = Naringenin and 17beta-estradiol coadministration prevents hormone-induced human cancer cell growth | journal = IUBMB Life | volume = 62 | issue = 1 | pages = 51–60 | date = January 2010 | pmid = 19960539 | doi = 10.1002/iub.279 | s2cid = 7903757 | doi-access = free }}</ref><ref name=pome>{{cite journal | vauthors = Sreeja S, Santhosh Kumar TR, Lakshmi BS, Sreeja S | title = Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation | journal = The Journal of Nutritional Biochemistry | volume = 23 | issue = 7 | pages = 725–32 | date = July 2012 | pmid = 21839626 | doi = 10.1016/j.jnutbio.2011.03.015 }}</ref> One of the functions of these estrogen receptors is the modulation of ]. Once estradiol binds to the ERs, the receptor complexes then bind to specific ], possibly causing damage to the DNA and an increase in cell division and ]. ]s respond to damaged DNA by stimulating or impairing G1, S, or G2 phases of the cell cycle to initiate ]. As a result, cellular transformation and cancer cell proliferation occurs.<ref name=estrogen>{{cite journal | vauthors = Thomas CG, Strom A, Lindberg K, Gustafsson JA | title = Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G₂/M checkpoint signaling | journal = Breast Cancer Research and Treatment | volume = 127 | issue = 2 | pages = 417–27 | date = June 2011 | pmid = 20623183 | doi = 10.1007/s10549-010-1011-z | s2cid = 6752694 }}</ref>
			===Cardiovascular system===
			Estrogen affects certain ]s. Improvement in arterial blood flow has been demonstrated in ].<ref name="pmid7788912">{{cite journal | vauthors = Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA | title = 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease | journal = Circulation | volume = 92 | issue = 1 | pages = 24–30 | date = July 1995 | pmid = 7788912 | doi = 10.1161/01.CIR.92.1.24 }}</ref> 17-beta-estradiol (E2) is considered the most potent estrogen found in humans. E2 influences vascular function, apoptosis, and damage during cardiac ischemia and reperfusion. E2 can protect the heart and individual cardiac myocytes from injuries related to ischemia. After a heart attack or long periods of hypertension, E2 inhibits the adverse effects of pathologic remodeling of the heart.<ref>{{cite journal |last1=Knowlton |first1=A.A. |last2=Lee |first2=A.R. |title=Estrogen and the cardiovascular system |journal=Pharmacology & Therapeutics |date=July 2012 |volume=135 |issue=1 |pages=54–70 |doi=10.1016/j.pharmthera.2012.03.007 |pmid=22484805 |pmc=5688223 }}</ref>
			During ], high levels of estrogens, namely estradiol, increase ] and the risk of ].
			{{Venous thromboembolism incidence during pregnancy and the postpartum period}}
			===Other functions===
			Estradiol has complex effects on the ]. It affects the production of multiple ]s, including ]s, binding proteins, and proteins responsible for ].{{citation needed|date=February 2013}} In high amounts, estradiol can lead to ], for instance ].
			Certain gynecological conditions are dependent on estrogen, such as ], ]ta uteri, and ].{{Citation needed|date=February 2013}}
			==Biological activity==
			{{See also|Pharmacodynamics of estradiol#Mechanism of action}}
			Estradiol acts primarily as an ] of the ] (ER), a ] ]. There are two subtypes of the ER, ] and ], and estradiol potently binds to and activates both of these receptors. The result of ER activation is a modulation of ] and ] in ER-expressing ]s, which is the predominant mechanism by which estradiol mediates its biological effects in the body. Estradiol also acts as an agonist of ]s (mERs), such as ] (GPR30), a recently discovered non-nuclear receptor for estradiol, via which it can mediate a variety of rapid, non-] effects.<ref name="pmid24530924">{{cite journal | vauthors = Prossnitz ER, Barton M | title = Estrogen biology: new insights into GPER function and clinical opportunities | journal = Molecular and Cellular Endocrinology | volume = 389 | issue = 1–2 | pages = 71–83 | date = May 2014 | pmid = 24530924 | pmc = 4040308 | doi = 10.1016/j.mce.2014.02.002 }}</ref> Unlike the case of the ER, GPER appears to be ] for estradiol, and shows very low ] for other endogenous estrogens, such as estrone and ].<ref name="pmid17222505">{{cite journal | vauthors = Prossnitz ER, Arterburn JB, Sklar LA | title = GPR30: A G protein-coupled receptor for estrogen | journal = Mol. Cell. Endocrinol. | volume = 265–266 | pages = 138–42 | year = 2007 | pmid = 17222505 | pmc = 1847610 | doi = 10.1016/j.mce.2006.12.010 }}</ref> Additional mERs besides GPER include ], ], and ].<ref name="pmid23756388">{{cite journal | vauthors = Soltysik K, Czekaj P | title = Membrane estrogen receptors - is it an alternative way of estrogen action? | journal = Journal of Physiology and Pharmacology | volume = 64 | issue = 2 | pages = 129–42 | date = April 2013 | pmid = 23756388 }}</ref><ref name="pmid22538318">{{cite journal | vauthors = Micevych PE, Kelly MJ | title = Membrane estrogen receptor regulation of hypothalamic function | journal = Neuroendocrinology | volume = 96 | issue = 2 | pages = 103–10 | year = 2012 | pmid = 22538318 | pmc = 3496782 | doi = 10.1159/000338400 }}</ref>
			ERα/ERβ are in inactive state trapped in multimolecular chaperone complexes organized around the heat shock protein 90 (HSP90), containing p23 protein, and immunophilin, and located in majority in cytoplasm and partially in nucleus. In the E2 classical pathway or estrogen classical pathway, estradiol enters the ], where it interacts with ERs. Once bound E2, ERs dissociate from the molecular chaperone complexes and become competent to dimerize, migrate to nucleus, and to bind to specific DNA sequences (], ERE), allowing for gene transcription which can take place over hours and days.
			Given by ] in mice, estradiol is about 10-fold more potent than estrone and about 100-fold more potent than estriol.<ref name="Labhart2012">{{cite book|vauthors=Labhart A|title=Clinical Endocrinology: Theory and Practice|url=https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA548|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-96158-8|pages=548–|access-date=11 November 2018|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014156/https://books.google.com/books?id=DAgJCAAAQBAJ&pg=PA548|url-status=live}}</ref><ref name="Blackburn2007">{{cite book|vauthors=Tucker SB|title=Maternal, Fetal, & Neonatal Physiology: A Clinical Perspective|url=https://books.google.com/books?id=2y6zOSQcn14C&pg=PA43|year=2007|publisher=Elsevier Health Sciences|isbn=978-1-4160-2944-1|pages=43–|access-date=7 June 2017|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014156/https://books.google.com/books?id=2y6zOSQcn14C&pg=PA43|url-status=live}}</ref><ref name="Hall2015">{{cite book| vauthors = Hall JE |title=Guyton and Hall Textbook of Medical Physiology E-Book|url=https://books.google.com/books?id=krLSCQAAQBAJ&pg=PA1043|date=31 May 2015|publisher=Elsevier Health Sciences|isbn=978-0-323-38930-3|pages=1043–}}</ref> As such, estradiol is the main estrogen in the body, although the roles of estrone and estriol as estrogens are said not to be negligible.<ref name="Hall2015" />
			{{Selected biological properties of endogenous estrogens in rats}}
			==Biochemistry==
			], showing estradiol at bottom right.<ref name="HäggströmRichfield2014">{{cite journal | vauthors = Häggström M, Richfield D | year=2014 |title=Diagram of the pathways of human steroidogenesis|journal=WikiJournal of Medicine|volume=1|issue=1|doi=10.15347/wjm/2014.005|issn=2002-4436|doi-access=free}}</ref>]]
			===Biosynthesis===
			Estradiol, like other ]s, is derived from ]. After ] cleavage and using the Δ<sup>5</sup> or the Δ<sup>4</sup>- pathway, ] is the key intermediary. A portion of the androstenedione is converted to testosterone, which in turn undergoes conversion to estradiol by aromatase. In an alternative pathway, androstenedione is ] to ], which is subsequently converted to estradiol via ] (17β-HSD).<ref>{{cite book | vauthors = Boron WF, Boulpaep EL |title=Medical Physiology: A Cellular And Molecular Approach |publisher=Elsevier/Saunders |year=2003 |page=1300 |isbn=978-1-4160-2328-9}}</ref>
			During the reproductive years, most estradiol in women is produced by the ]s of the ovaries by the aromatization of androstenedione (produced in the theca folliculi cells) to estrone, followed by conversion of estrone to estradiol by 17β-HSD. Smaller amounts of estradiol are also produced by the ], and, in men, by the testes.{{medcn|date=February 2019}}
			Estradiol is not produced in the ]s only; in particular, ] produce active precursors to estradiol, and will continue to do so even after menopause.<ref name="Mutschler">{{Cite book| vauthors = Mutschler E, Schäfer-Korting M | title = Arzneimittelwirkungen|language=de|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=434, 444|isbn=978-3-8047-1763-3}}</ref> Estradiol is also produced in the ] and in ]s.
			In men, approximately 15 to 25% of circulating estradiol is produced in the ]s.<ref name="Melmed2016">{{cite book|vauthors=Melmed S|title=Williams Textbook of Endocrinology|url=https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA710|date=1 January 2016|publisher=Elsevier Health Sciences|isbn=978-0-323-29738-7|pages=710–|access-date=21 March 2018|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014157/https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA710|url-status=live}}</ref><ref name="MarcusFeldman2013">{{cite book| vauthors = Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA |title= Osteoporosis |url= https://books.google.com/books?id=b1FtazykqzMC&pg=PA331 |date=13 June 2013|publisher=Academic Press|isbn=978-0-12-398252-0|pages=331–}}</ref> The rest is synthesized via peripheral aromatization of testosterone into estradiol and of androstenedione into estrone (which is then transformed into estradiol via peripheral 17β-HSD).<ref name="Melmed2016" /><ref name="MarcusFeldman2013" /> This peripheral aromatization occurs predominantly in ], but also occurs in other ]s such as ], ], and the ].<ref name="Melmed2016" /> Approximately 40 to 50&nbsp;μg of estradiol is produced per day in men.<ref name="Melmed2016" />
			===Distribution===
			In plasma, estradiol is largely bound to SHBG and ]. Only about 2.21% (± 0.04%) of estradiol is free and biologically active. The percentage remains constant throughout the ].<ref>{{cite journal | vauthors = Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G | title = Free and protein-bound plasma estradiol-17 beta during the menstrual cycle | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 43 | issue = 2 | pages = 436–45 | date = August 1976 | pmid = 950372 | doi = 10.1210/jcem-43-2-436 }}</ref>
			===Metabolism===
			{{See also|Catechol estrogen|Estrogen conjugate|Hydroxylation of estradiol}}
			{{Estradiol metabolism|align=right}}
			Inactivation of estradiol includes conversion to less-active estrogens, such as estrone and estriol. Estriol is the major urinary ].{{Citation needed|date=December 2016}} Estradiol is ] in the ] to form ]s like ], ] and, as such, excreted via the ]s. Some of the water-soluble conjugates are excreted via the ], and partly reabsorbed after ] from the ]. This ] contributes to maintaining estradiol levels.
			Estradiol is also metabolized via ] into ]s. In the liver, it is non-specifically metabolized by ], ], and ] via 2-hydroxylation into ], and by ], ], and ] via 17β-hydroxy dehydrogenation into ],<ref name="pmid11741520">{{cite journal | vauthors = Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH | title = Role of cytochrome P450 in estradiol metabolism in vitro | journal = Acta Pharmacologica Sinica | volume = 22 | issue = 2 | pages = 148–54 | date = February 2001 | pmid = 11741520 }}</ref> with various other ] (CYP) ]s and ]s also being involved.<ref name="pmid12865317">{{cite journal | vauthors = Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT | title = Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms | journal = Endocrinology | volume = 144 | issue = 8 | pages = 3382–98 | date = August 2003 | pmid = 12865317 | doi = 10.1210/en.2003-0192 | doi-access = free }}</ref>
			Estradiol is additionally ] with an ] into ] forms like ] and ] to a certain extent; these esters are stored in ] and may act as a very long-lasting reservoir of estradiol.<ref name="OettelSchillinger2012A">{{cite book| vauthors = Oettel M, Schillinger E |title=Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens|url=https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA235|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-58616-3|pages=235–237}}</ref><ref name="OettelSchillinger2012B">{{cite book| vauthors = Oettel M, Schillinger E |title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA268|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=268, 271}}</ref>
			===Excretion===
			Estradiol is ] in the form of ] and ] ]s in ]. Following an ] of ] estradiol in women, almost 90% is excreted in urine and ] within 4 to 5&nbsp;days.<ref name="Dorfman1961">{{cite book|last1=Dorfman|first1=Ralph I.|title=Radioactive Isotopes in Physiology Diagnostics and Therapy / Künstliche Radioaktive Isotope in Physiologie Diagnostik und Therapie|chapter=Steroid Hormone Metabolism|year=1961|pages=1223–1241|doi=10.1007/978-3-642-49761-2_39|isbn=978-3-642-49477-2}}</ref><ref name="pmid13463090">{{cite journal | vauthors = Sandberg AA, Slaunwhite WR | title = Studies on phenolic steroids in human subjects. II. The metabolic fate and hepato-biliary-enteric circulation of C14-estrone and C14-estradiol in women | journal = J. Clin. Invest. | volume = 36 | issue = 8 | pages = 1266–78 | date = August 1957 | pmid = 13463090 | pmc = 1072719 | doi = 10.1172/JCI103524}}</ref> ] causes a delay in excretion of estradiol.<ref name="Dorfman1961" />
			===Levels===
			]
			Levels of estradiol in premenopausal women are highly variable throughout the menstrual cycle and reference ranges widely vary from source to source.<ref name="BeckerBerkley2007">{{cite book | vauthors = Becker JB, Berkley KJ, Geary N, Hampson E, Herman JP, Young E |author-link5=James P. Herman |title=Sex Differences in the Brain: From Genes to Behavior|url=https://books.google.com/books?id=IeaLXPWsbuAC&pg=PA64|date=4 December 2007|publisher=Oxford University Press|isbn=978-0-19-804255-6|pages=64–|quote=Estradiol levels are minimal during the earliest days of the follicular phase, but increasing concentrations are released into the general circulation as the follicle matures. The highest levels are reached about 24 to 48 hours before the LH peak. In fact, the pre-ovulatory peak in estradiol represents its highest concentration during the entire menstrual cycle. Serum concentrations at this time are typically about 130–200 pg/mL, but concentrations as high as 300–400 pg/mL can be achieved in some women. Following a transient fall in association with ovulation, estradiol secretion is restored by production from the corpus luteum during the luteal phase. Plateau levels of around 100–150 pg/mL (Abraham, 1978; Thorneycroft et al., 1971) are most often seen during the period from −10 to −5 days before the onset of menses. With the regression of the corpus luteum, estradiol levels fall, gradually in some women and precipitously in others, during the last few days of the luteal phase. This ushers in the onset of menses, the sloughing of the endometrium. Serum estradiol during menses is approximately 30–50 pg/mL. (Source.)}}</ref> Estradiol levels are minimal and according to most laboratories range from 20 to 80&nbsp;pg/mL during the early to mid follicular phase (or the first week of the menstrual cycle, also known as menses).<ref name="StraussBarbieri2009">{{cite book|vauthors=Strauss JR, Barbieri RL|title=Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management|url=https://books.google.com/books?id=NudwnhxY8kYC&pg=PA807|year=2009|publisher=Elsevier Health Sciences|isbn=978-1-4160-4907-4|pages=807–|quote=In most laboratories, serum estradiol levels range from 20 to 80 pg/mL during the early to midfollicular phase of the menstrual cycle and peak at 200 to 500 pg/mL during the preovulatory surge. During the midluteal phase, serum estradiol levels range from 60 to 200 pg/mL.|access-date=21 December 2016|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014157/https://books.google.com/books?id=NudwnhxY8kYC&pg=PA807|url-status=live}}</ref><ref name="ChristianSchoultz1994" /> Levels of estradiol gradually increase during this time and through the mid to late follicular phase (or the second week of the menstrual cycle) until the pre-ovulatory phase.<ref name="BeckerBerkley2007" /><ref name="StraussBarbieri2009" /> At the time of pre-ovulation (a period of about 24 to 48&nbsp;hours), estradiol levels briefly surge and reach their highest concentrations of any other time during the menstrual cycle.<ref name="BeckerBerkley2007" /> Circulating levels are typically between 130 and 200&nbsp;pg/mL at this time, but in some women may be as high as 300 to 400&nbsp;pg/mL, and the upper limit of the reference range of some laboratories are even greater (for instance, 750&nbsp;pg/mL).<ref name="BeckerBerkley2007" /><ref name="StraussBarbieri2009" /><ref name="JamesonGroot2010">{{cite book | vauthors = Jameson JL, De Groot LJ | title=Endocrinology: Adult and Pediatric | url = https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2812|date=18 May 2010|publisher=Elsevier Health Sciences|isbn=978-1-4557-1126-0|pages=2812–|quote=Midcycle: 150-750 pg/mL}}</ref><ref name="HayWass2009">{{cite book | vauthors = Hay ID, Wass JA |title=Clinical Endocrine Oncology|url=https://books.google.com/books?id=fGio-5vtqqkC&pg=PA623|date=26 January 2009|publisher=John Wiley & Sons|isbn=978-1-4443-0023-9|pages=623–|quote=Mid-cycle: 110-330 pg/mL}}</ref><ref name="Dons1994">{{cite book| vauthors = Dons RF |title=Endocrine and Metabolic Testing Manual|url=https://books.google.com/books?id=w8jGxo_xoI4C&pg=SA8-PA8|date=12 July 1994|publisher=CRC Press|isbn=978-0-8493-7657-3|pages=8–|quote=Ovulatory: 200-400 pg/mL}}</ref> Following ovulation (or mid-cycle) and during the latter half of the menstrual cycle or the luteal phase, estradiol levels plateau and fluctuate between around 100 and 150&nbsp;pg/mL during the early and mid luteal phase, and at the time of the late luteal phase, or a few days before menstruation, reach a low of around 40&nbsp;pg/mL.<ref name="BeckerBerkley2007" /><ref name="ChristianSchoultz1994" /> The mean integrated levels of estradiol during a full menstrual cycle have variously been reported by different sources as 80, 120, and 150&nbsp;pg/mL.<ref name="ChristianSchoultz1994">{{cite book | vauthors = Christian C, von Schoultz B| title = Hormone Replacement Therapy: Standardized or Individually Adapted Doses?|url=https://books.google.com/books?id=apU4AfUqSGwC&pg=PA60|date=15 March 1994|publisher=CRC Press|isbn=978-1-85070-545-1|pages=60–|quote=Plasma levels of estradiol range from 40 to 80 pg/mL during the 1st week of the ovarian cycle (early follicular phase) and from 80 to 300 pg/mL during the 2nd week (mid- and late follicular phase including periovulatory peak). Then during the 3rd and 4th weeks, estradiol fluctuates between 100 and 150 pg/mL (early and mid-luteal phase) to 40 pg/mL a few days before menstruation (late luteal phase). The mean integrated estradiol level during a full 28-day normal cycle is around 80 pg/mL.}}</ref><ref name="NotelovitzKeep2012">{{cite book|vauthors=Notelovitz M, van Keep PA|title=The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28 – November 2, 1984|url=https://books.google.com/books?id=VM0hBQAAQBAJ&pg=PA397|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-4145-8|pages=397–|quote= following the menopause, circulating estradiol levels decrease from a premenopausal mean of 120 pg/mL to only 13 pg/mL.|access-date=22 October 2016|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014157/https://books.google.com/books?id=VM0hBQAAQBAJ&pg=PA397|url-status=live}}</ref><ref name="MüllerMacLeod2012">{{cite book|vauthors=Müller EE, MacLeod RM|title=Neuroendocrine Perspectives|url=https://books.google.com/books?id=TUXtBwAAQBAJ&pg=PA121|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-3554-5|pages=121–|quote= mean concentration of 150 pg/mL |access-date=22 October 2016|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014157/https://books.google.com/books?id=TUXtBwAAQBAJ&pg=PA121|url-status=live}}</ref> Although contradictory reports exist, one study found mean integrated estradiol levels of 150&nbsp;pg/mL in younger women whereas mean integrated levels ranged from 50 to 120&nbsp;pg/mL in older women.<ref name="MüllerMacLeod2012" />
			During the reproductive years of human females, levels of estradiol are somewhat higher than that of estrone, except during the early follicular phase of the menstrual cycle; thus, estradiol may be considered the predominant estrogen during human female reproductive years in terms of absolute serum levels and estrogenic activity.{{citation needed|date=June 2014}} During pregnancy, estriol becomes the predominant circulating estrogen, and this is the only time at which estetrol occurs in the body, while during menopause, estrone predominates (both based on serum levels).{{citation needed|date=June 2014}} The estradiol produced by male humans, from testosterone, is present at serum levels roughly comparable to those of ] women (14–55 versus <35 pg/mL, respectively).{{citation needed|date=June 2014}} It has also been reported that if concentrations of estradiol in a 70-year-old man are compared to those of a 70-year-old woman, levels are approximately 2- to 4-fold higher in the man.<ref name="pmid14644018">{{cite journal | vauthors = Sayed Y, Taxel P | title = The use of estrogen therapy in men | journal = Current Opinion in Pharmacology | volume = 3 | issue = 6 | pages = 650–4 | date = December 2003 | pmid = 14644018 | doi = 10.1016/j.coph.2003.07.004}}</ref>
			{| class="wikitable sortable mw-collapsible" style="margin: 1em auto;"
			|+ class="nowrap" | Endogenous <noinclude>]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>]</noinclude><includeonly>estrogen</includeonly> levels
			|-
			! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
			|-
			| ] girls<sup>a</sup><br />&nbsp;&nbsp;] (childhood)<br />&nbsp;&nbsp;] (ages 8–12)<br />&nbsp;&nbsp;] (ages 10–13)<br />&nbsp;&nbsp;] (ages 11–14)<br />&nbsp;&nbsp;] (ages 12–15)<br />&nbsp;&nbsp;&nbsp;&nbsp;] (days 1–14)<br />&nbsp;&nbsp;&nbsp;&nbsp;] (days 15–28) || &nbsp;<br />?<br />?<br />?<br />?<br />&nbsp;<br />?<br />? || &nbsp;<br />9 (<9–20) pg/mL<br />15 (<9–30) pg/mL<br />27 (<9–60) pg/mL<br />55 (16–85) pg/mL<br />&nbsp;<br />50 (30–100) pg/mL<br />130 (70–300) pg/mL || &nbsp;<br />13 (<9–23) pg/mL<br />18 (10–37) pg/mL<br />26 (17–58) pg/mL<br />36 (23–69) pg/mL<br />&nbsp;<br />44 (30–89) pg/mL<br />75 (39–160) pg/mL || &nbsp;<br />?<br />?<br />?<br />?<br />&nbsp;<br />?<br />?
			|-
			| ] boys || ? || 2–8 pg/mL || ? || ?
			|-
			| ] women<br />&nbsp;&nbsp;] (days 1–4)<br />&nbsp;&nbsp;] (days 5–9)<br />&nbsp;&nbsp;] (days 10–14)<br />&nbsp;&nbsp;] (days 15–28)<br />&nbsp;&nbsp;] (]) || &nbsp;<br />30–100&nbsp;μg/day<br />100–160&nbsp;μg/day<br />320–640&nbsp;μg/day<br />300&nbsp;μg/day<br />? || &nbsp;<br />40–60 pg/mL<br />60–100 pg/mL<br />200–400 pg/mL<br />190 pg/mL<br />12–50 pg/mL || &nbsp;<br />40–60 pg/mL<br />?<br />170–200 pg/mL<br />100–150 pg/mL<br />? || &nbsp;<br />0.5–1<br />?<br />1–2<br />1.5<br />?
			|-
			| ] women || 18&nbsp;μg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
			|-
			| ] women<br />&nbsp;&nbsp;] (weeks 1–12)<br />&nbsp;&nbsp;] (weeks 13–26)<br />&nbsp;&nbsp;] (weeks 27–40) || &nbsp;<br />?<br />?<br />? || &nbsp;<br />1,000–5,000 pg/mL<br />5,000–15,000 pg/mL<br />10,000–40,000 pg/mL || &nbsp;<br />?<br />?<br />? || &nbsp;<br />?<br />?<br />?
			|-
			| Men<sup>a</sup> || 20–60&nbsp;μg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
			|- class="sortbottom"
			| colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Footnotes:''' <sup>a</sup> = Format is "mean value (range)" or just "range". '''Sources:''' <noinclude><ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = 10.1097/00006254-198404000-00022 }}</ref><ref name="CherneckyBerger2012">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=978-1-4557-4502-9|pages=488–|access-date=22 August 2023|archive-date=22 August 2023|archive-url=https://web.archive.org/web/20230822235743/https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|url-status=live}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 }}</ref><ref name="Becker2001">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011" /><ref name="Abbott2009" /><ref name="Kuhl2003" /></noinclude><includeonly>See template.</includeonly>
			|}
	==Measurement==		====Measurement====
	In women, serum estradiol is measured in a ] and reflects primarily the activity of the ovaries. As such, they are useful in the detection of baseline estrogen in women with ] or menstrual dysfunction, and to detect the state of hypoestrogenicity and ]. Furthermore, estrogen monitoring during fertility therapy assesses follicular growth and is useful in monitoring the treatment. Estrogen-producing tumors will demonstrate persistent high levels of estradiol and other estrogens. In ], estradiol levels are inappropriately increased.		In women, serum estradiol is measured in a ] and reflects primarily the activity of the ovaries. The Estradiol blood test measures the amount of estradiol in the blood.<ref name=":0" /> It is used to check the function of the ovaries, placenta, adrenal glands.<ref name=":0" /> This can detect baseline estrogen in women with ] or menstrual dysfunction, and to detect the state of hypoestrogenicity and menopause. Furthermore, estrogen monitoring during fertility therapy assesses follicular growth and is useful in monitoring the treatment. Estrogen-producing tumors will demonstrate persistent high levels of estradiol and other estrogens. In ], estradiol levels are inappropriately increased.
	===Ranges===		====Ranges====
			Individual laboratory results should always be interpreted using the ranges provided by the laboratory that performed the test.
	] of estradiol during the ]<ref>References and further description of values are given in image page in Wikimedia Commons at ].</ref>
	<br>- The ranges denoted '''By biological stage''' may be used in closely monitored menstrual cycles in regard to other markers of its biological progression, with the time scale being compressed or stretched to how much faster or slower, respectively, the cycle progresses compared to an average cycle.
	<br>- The ranges denoted '''Inter-cycle variability''' are more appropriate to use in unmonitored cycles with only the beginning of menstruation known, but where the woman accurately knows her average cycle lengths and time of ovulation, and that they are somewhat averagely regular, with the time scale being compressed or stretched to how much a woman's average cycle length is shorter or longer, respectively, than the average of the population.
	<br>- The ranges denoted '''Inter-woman variability''' are more appropriate to use when the average cycle lengths and time of ovulation are unknown, but only the beginning of menstruation is given.]]
	{| class="wikitable" align="left"		{| class="wikitable" align="left"
	!colspan=4| ] estradiol		|+ ] estradiol
	|-		|-
			! Patient type
	|'''Patient type'''||'''Lower limit'''||'''Upper limit'''||'''Unit'''
			! Lower limit
			! Upper limit
			! Unit
	|-		|-
	|rowspan=2| Adult male || 50<ref name=gpnotebook-estradiol> Retrieved on September 27, 2009</ref> || 200<ref name=gpnotebook-estradiol/> || pmol/L		| rowspan=2| Adult male || 50<ref name="gpnotebook-estradiol"> {{Webarchive|url=https://web.archive.org/web/20120609174939/http://www.gpnotebook.co.uk/simplepage.cfm?ID=570818627&linkID=24801&cook=yes |date=9 June 2012 }} Retrieved on 27 September 2009</ref> || 200<ref name="gpnotebook-estradiol"/> || pmol/L
	|-		|-
	| 14 || 55 || pg/mL		| 14 || 55 || pg/mL
	|-
	|rowspan=4| Adult female (], day 5) || 70<ref name=gpnotebook-estradiol/><br><font size=1>95% ] (standard) || 500<ref name=gpnotebook-estradiol/><br><font size=1>95% PI ||rowspan=2| pmol/L
	|-		|-
			| rowspan=4| Adult female (], day 5) || 70<ref name="gpnotebook-estradiol"/><br /><span style="font-size:87%;">95% ] (standard)</span> || 500<ref name="gpnotebook-estradiol"/><br /><span style="font-size:87%;">95% PI</span> || rowspan=2 | pmol/L
	| 110<ref name=Stricker>Values taken from day 1 after LH surge in: {{cite journal |author=Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R |title=Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer |journal=Clin. Chem. Lab. Med. |volume=44 |issue=7 |pages=883–7 |year=2006 |pmid=16776638 |doi=10.1515/CCLM.2006.160 |url=http://www.reference-global.com/doi/abs/10.1515/CCLM.2006.160?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed}} </ref><br><font size=1>90% ] (used <br>in ]) || 220<ref name=Stricker/><br><font size=1>90% PI
	|-		|-
			| 110<ref name=Stricker>Values taken from day 1 after LH surge in: {{cite journal | vauthors = Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R | title = Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer | journal = Clinical Chemistry and Laboratory Medicine | volume = 44 | issue = 7 | pages = 883–7 | year = 2006 | pmid = 16776638 | doi = 10.1515/CCLM.2006.160 | s2cid = 524952 }} </ref><br /><span style="font-size:87%;">90% ] (used <br />in ])</span> || 220<ref name=Stricker/><br /><span style="font-size:87%;">90% PI</span>
	| 19 <font size=1>(95% PI) || 140 <font size=1>(95% PI) ||rowspan=2| pg/mL
	|-		|-
	| 30 <font size=1>(90% PI) || 60 <font size=1>(90% PI)		| 19 <span style="font-size:87%;">(95% PI)</span> || 140 <span style="font-size:87%;">(95% PI)</span> || rowspan=2 | pg/mL
	|-		|-
			| 30 <span style="font-size:87%;">(90% PI)</span> || 60 <span style="font-size:87%;">(90% PI)</span>
	|rowspan=2| Adult female (]<br> peak) || 400<ref name=gpnotebook-estradiol/> || 1500<ref name=gpnotebook-estradiol/> || pmol/L
	|-		|-
			| rowspan=2| Adult female (]<br /> peak) || 400<ref name="gpnotebook-estradiol"/> || 1500<ref name="gpnotebook-estradiol"/> || pmol/L
	| 110 || 410 || pg/mL
	|-		|-
			| 110 || 410 || pg/mL
	|rowspan=2| Adult female <br>(]) || 70<ref name=gpnotebook-estradiol/> || 600<ref name=gpnotebook-estradiol/> || pmol/L
	|-		|-
			| rowspan=2| Adult female <br />(]) || 70<ref name="gpnotebook-estradiol"/> || 600<ref name="gpnotebook-estradiol"/> || pmol/L
	| 19 || 160 || pg/mL
	|-		|-
			| 19 || 160 || pg/mL
	|rowspan=2| Adult female - free <br>(not protein bound) || 0.5<ref name=free-estradiol>Total amount multiplied by 0.022 according to 2.2% presented in: {{cite journal |author=Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G |title=Free and protein-bound plasma estradiol-17 beta during the menstrual cycle |journal=J. Clin. Endocrinol. Metab. |volume=43 |issue=2 |pages=436–45 |year=1976 |month=August |pmid=950372 |doi= 10.1210/jcem-43-2-436}}</ref> || 9<ref name=free-estradiol/> || pg/mL
	|-		|-
			| rowspan=2| Adult female – free <br />(not protein bound) || 0.5<ref name="free-estradiol">Total amount multiplied by 0.022 according to 2.2% presented in: {{cite journal | vauthors = Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G | title = Free and protein-bound plasma estradiol-17 beta during the menstrual cycle | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 43 | issue = 2 | pages = 436–45 | date = August 1976 | pmid = 950372 | doi = 10.1210/jcem-43-2-436 }}{{Original research inline|date=June 2014}}</ref>{{Original research inline|date=June 2014}} || 9<ref name="free-estradiol"/>{{Original research inline|date=June 2014}} || pg/mL
	| 1.7<ref name=free-estradiol/> || 33<ref name=free-estradiol/> || pmol/L
	|-		|-
	|rowspan=2| Post-menopausal female || N/A<ref name=gpnotebook-estradiol/> || < 130<ref name=gpnotebook-estradiol/> || pmol/L		| 1.7<ref name="free-estradiol"/>{{Original research inline|date=June 2014}} || 33<ref name="free-estradiol"/>{{Original research inline|date=June 2014}} || pmol/L
	|-		|-
			| rowspan=2| Post-menopausal female || N/A<ref name="gpnotebook-estradiol"/> || < 130<ref name="gpnotebook-estradiol"/> || pmol/L
	| N/A || < 35 || pg/mL
			|-
			| N/A || < 35 || pg/mL
	|-		|-
	|}		|}
	<br clear="all">		{{clear}}
			{{Hidden begin|toggle=left|title=Reference ranges for the blood content of estradiol during the menstrual cycle}}
	In the normal ], estradiol levels measure typically <50&nbsp;pg/ml at menstruation, rise with follicular development (peak: 200 pg/ml), drop briefly at ovulation, and rise again during the luteal phase for a second peak. At the end of the luteal phase, estradiol levels drop to their menstrual levels unless there is a pregnancy.
			] of estradiol during the ]
			<br />- The ranges denoted '''By biological stage''' may be used in closely monitored menstrual cycles in regard to other markers of its biological progression, with the time scale being compressed or stretched to how much faster or slower, respectively, the cycle progresses compared to an average cycle.
			<br />- The ranges denoted '''Inter-cycle variability''' are more appropriate to use in unmonitored cycles with only the beginning of menstruation known, but where the woman accurately knows her average cycle lengths and time of ovulation, and that they are somewhat averagely regular, with the time scale being compressed or stretched to how much a woman's average cycle length is shorter or longer, respectively, than the average of the population.
			<br />- The ranges denoted '''Inter-woman variability''' are more appropriate to use when the average cycle lengths and time of ovulation are unknown, but only the beginning of menstruation is given.<ref name="Häggström2014">{{cite journal|year=2014|title=Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle|journal=WikiJournal of Medicine|volume=1|issue=1|doi=10.15347/wjm/2014.001|issn=2002-4436| vauthors = Häggström M |doi-access=free}}</ref>]]
			{{Hidden end}}
			In the normal menstrual cycle, estradiol levels measure typically <50&nbsp;pg/mL at menstruation, rise with follicular development (peak: 200 pg/mL), drop briefly at ovulation, and rise again during the luteal phase for a second peak. At the end of the luteal phase, estradiol levels drop to their menstrual levels unless there is a pregnancy.
	During ], estrogen levels, including estradiol, rise steadily toward term. The source of these estrogens is the ], which aromatizes prohormones produced in the fetal adrenal gland.
			During pregnancy, estrogen levels, including estradiol, rise steadily toward term. The source of these estrogens is the ], which aromatizes ]s produced in the fetal adrenal gland.
	==Effects==
	===Female reproduction===
	In the female, estradiol acts as a growth hormone for tissue of the reproductive organs, supporting the lining of the ], the cervical glands, the ], and the lining of the fallopian tubes. It enhances growth of the ]. Estradiol appears necessary to maintain ]s in the ]. During the ], estradiol produced by the growing follicle triggers, via a positive feedback system, the hypothalamic-pituitary events that lead to the ] surge, inducing ovulation. In the luteal phase, estradiol, in conjunction with ], prepares the endometrium for ]. During ], estradiol increases due to ]l production. In baboons, blocking of estrogen production leads to pregnancy loss, suggesting estradiol has a role in the maintenance of pregnancy. Research is investigating the role of estrogens in the process of initiation of ]. Actions of estradiol are required before prior exposure of progesterone in the luteal phase.
			{{Production rates, secretion rates, clearance rates, and blood levels of major sex hormones}}
	===Sexual development===
	The development of ] in women is driven by estrogens, to be specific, estradiol. These changes are initiated at the time of puberty, most are enhanced during the reproductive years, and become less pronounced with declining estradiol support after the menopause. Thus, estradiol enhances breast development, and is responsible for changes in the body shape, affecting bones, joints and fat deposition. Fat structure and skin composition are modified by estradiol.
			==Medical use==
	===Male reproduction===
			{{Main|Estradiol (medication)|Pharmacodynamics of estradiol|Pharmacokinetics of estradiol}}
	The effect of estradiol (and estrogens) upon male reproduction is complex. Estradiol is produced by action of ] mainly in the ]s of the mammalian testis, but also by some ]s and the ]s of immature mammals <ref>{{cite journal | last1 = Carreau | first1 = S | last2 = Lambard | first2 = S | last3 = Delalande | first3 = C | last4 = Denis-Galeraud | first4 = I | last5 = Bourguiba | first5 = S | title = Aromatase expression and role of estrogens in male gonad : a review | journal = Reproductive Biology and Endocrinology | volume = 1 | pages = 35 | year = 2003 | pmid = 12747806 | doi=10.1186/1477-7827-1-35 | last6 = Bourguiba | first6 = Sonia | pmc = 155680 }}</ref>. It functions to prevent ] of male sperm cells.<ref>{{cite journal | last1 = Pentikäinen | first1 = V | last2 = Erkkilä | first2 = K | last3 = Suomalainen | first3 = L | last4 = Parvinen | first4 = M | last5 = Dunkel | first5 = L | title = Estradiol acts as a germ cell survival factor in the human testis in vitro | journal = The Journal of clinical endocrinology and metabolism | volume = 85 | issue = 5 | pages = 2057–67 | year = 2000 | pmid = 10843196 | doi=10.1210/jc.85.5.2057}}</ref>
			Estradiol is used as a ], primarily in ] for ] ]s as well as ] for trans individuals.<ref name="pmid16112947" />
	Several studies have noted ]s have been declining in many parts of the world, and estrogen exposure in the environment has been postulated to be the cause.<ref>{{cite journal | last1 = Sharpe | first1 = RM | last2 = Skakkebaek | first2 = NE | title = Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? | journal = Lancet | volume = 341 | issue = 8857 | pages = 1392–5 | year = 1993 | pmid = 8098802 | doi=10.1016/0140-6736(93)90953-E}}</ref> Suppression of estradiol production in a subpopulation of subfertile men may improve the semen analysis.<ref>{{cite journal | last1 = Raman | first1 = JD | last2 = Schlegel | first2 = PN | title = Aromatase inhibitors for male infertility | journal = The Journal of urology | volume = 167 | issue = 2 Pt 1 | pages = 624–9 | year = 2002 | pmid = 11792932 | doi=10.1016/S0022-5347(01)69099-2}}</ref>
			==Chemistry==
	Males with sex chromosome genetic conditions, such as ], will have a higher level of estradiol.
			{{See also|List of estrogens}}
			{{Chemical structures of major endogenous estrogens|align=right|caption=Note the ] (–OH) ]s: estrone (E1) has one, estradiol (E2) has two, estriol (E3) has three, and estetrol (E4) has four.}}
			Estradiol is an ] ].<ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | s2cid = 24616324 | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 | issue = 1 Suppl 1 | pages = 3–63 | date = August 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 }}</ref> It is also known as 17β-estradiol (to distinguish it from ]) or as estra-1,3,5(10)-triene-3,17β-diol. It has two ]s, one at the C3 position and the other at the 17β position, as well as three ]s in the A ]. Due to its two hydroxyl groups, estradiol is often abbreviated as E2. The structurally related estrogens, estrone (E1), estriol (E3), and ] (E4) have one, three, and four hydroxyl groups, respectively.
	===Bone===
	Estradiol has a profound effect on bone. Individuals without it (or other estrogens) will become tall and eunuchoid, as ] closure is delayed or may not take place. Bone structure is affected also, resulting in early ] and ].<ref>{{cite journal | last1 = Carani | first1 = C | last2 = Qin | first2 = K | last3 = Simoni | first3 = M | last4 = Faustini-Fustini | first4 = M | last5 = Serpente | first5 = S | last6 = Boyd | first6 = J | last7 = Korach | first7 = KS | last8 = Simpson | first8 = ER | title = Effect of testosterone and estradiol in a man with aromatase deficiency | journal = The New England journal of medicine | volume = 337 | issue = 2 | pages = 91–5 | year = 1997 | pmid = 9211678 | doi = 10.1056/NEJM199707103370204 }}</ref> Also, women past menopause experience an accelerated loss of bone mass due to a relative estrogen deficiency.
			==Neuropsychopharmacology==
	===Liver===
			Product insert information, accompanying commercial perscription estradiol, indicates it causes depression.
	Estradiol has complex effects on the liver. It can lead to ]. It affects the production of multiple proteins, including ]s, binding proteins, and proteins responsible for ].
			In a randomized, double-blind, placebo-controlled study, estradiol was shown to have gender-specific effects on fairness sensitivity. Overall, when the division of a given amount of money was framed as either fair or unfair in a modified version of the ], estradiol increased the acceptance rate of fair-framed proposals among men and decreased it among women. However, among the placebo-group "the mere belief of receiving estradiol treatment significantly increased the acceptance of unfair-framed offers in both sexes", indicating that so-called "environmental" factors played a role in organising the responses towards these presentations of the ].<ref>{{cite journal | vauthors = Coenjaerts M, Pape F, Santoso V, Grau F, Stoffel-Wagner B, Philipsen A, Schultz J, Hurlemann R, Scheele D |title=Sex differences in economic decision-making: Exogenous estradiol has opposing effects on fairness framing in women and men. |journal=Eur. Neuropsychopharmacol. |volume=50 |issue=2 |pages=46–54 |date= September 2021|pmid=33957337|doi= 10.1016/j.euroneuro.2021.04.006 | issn=0924-977X|s2cid=233982738 |hdl=20.500.11811/11066 |hdl-access=free }}</ref>
	===Brain===		==History==
			{{See also|Estrone#History}}
	Estrogens can be produced in the brain from steroid precursors. As ], they have been found to have neuroprotective function.<ref>{{cite journal |author=Behl C, Widmann M, Trapp T, Holsboer F |title=17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro |journal=Biochem. Biophys. Res. Commun. |volume=216 |issue=2 |pages=473–82 |year=1995 |month=November |pmid=7488136 |doi=10.1006/bbrc.1995.2647 }}</ref>
			The discovery of estrogen is usually credited to the ] ]s ] and ].<ref name="LoriauxLoriaux2016">{{cite book | vauthors = Loriaux DL, Loriaux L |title=A Biographical History of Endocrinology|url=https://books.google.com/books?id=pkWhCwAAQBAJ&pg=PA345|date=14 March 2016|publisher=John Wiley & Sons|isbn=978-1-119-20246-2|pages=345–}}</ref><ref name="LauritzenStudd2005">{{cite book | vauthors = Lauritzen C, Studd JW |title=Current Management of the Menopause|url=https://books.google.com/books?id=WD7S7677xUUC&pg=PA44|date=22 June 2005|publisher=CRC Press|isbn=978-0-203-48612-2|pages=44–}}</ref> In 1923, they observed that injection of fluid from ] ]s produced ]- and ]-type changes (including ]l, ], and ] changes and ]) in ], ] mice and rats.<ref name="LoriauxLoriaux2016" /><ref name="LauritzenStudd2005" /><ref name="AllenDoisy1923">{{cite journal | vauthors = Allen E, Doisy EA | title = An Ovarian Hormone | journal = Journal of the American Medical Association |volume=81 |issue=10 |year=1923 |pages=819 |issn=0002-9955 |doi=10.1001/jama.1923.02650100027012 }}</ref> These findings demonstrated the existence of a ] which is produced by the ] and is involved in ] and ].<ref name="LoriauxLoriaux2016" /><ref name="LauritzenStudd2005" /><ref name="AllenDoisy1923" /> At the time of its discovery, Allen and Doisy did not name the hormone, and simply referred to it as an "ovarian hormone" or "follicular hormone";<ref name="LauritzenStudd2005" /> others referred to it variously as ''feminin'', ''folliculin'', ''menformon'', ''thelykinin'', and ''emmenin''.<ref name="GruhnKazer2013">{{cite book | vauthors = Gruhn JG, Kazer RR |title=Hormonal Regulation of the Menstrual Cycle: The Evolution of Concepts|url=https://books.google.com/books?id=lFn0BwAAQBAJ&pg=PA69|date=11 November 2013|publisher=Springer Science & Business Media|isbn=978-1-4899-3496-3|pages=69–73}}</ref><ref name="Newerla1944">{{cite journal| vauthors = Newerla GJ |title=The History of the Discovery and Isolation of the Female Sex Hormones|journal=New England Journal of Medicine|volume=230|issue=20|year=1944|pages=595–604|issn=0028-4793|doi=10.1056/NEJM194405182302001}}</ref> In 1926, Parkes and Bellerby coined the term ''estrin'' to describe the hormone on the basis of it inducing ] in animals.<ref name="FritzSperoff2012">{{cite book | vauthors = Fritz MA, Speroff L |title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=KZLubBxJEwEC&pg=PA750|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4847-3|pages=750–}}</ref><ref name="GruhnKazer2013" /> ] was isolated and purified independently by Allen and Doisy and ] scientist ] in 1929, and ] was isolated and purified by Marrian in 1930; they were the first estrogens to be identified.<ref name="LauritzenStudd2005" /><ref name="Parl2000">{{cite book|vauthors=Parl FF|title=Estrogens, Estrogen Receptor and Breast Cancer|url=https://books.google.com/books?id=v7ai5Mz9TZQC&pg=PA4|year=2000|publisher=IOS Press|isbn=978-0-9673355-4-4|pages=4–|access-date=27 November 2016|archive-date=10 January 2023|archive-url=https://web.archive.org/web/20230110014157/https://books.google.com/books?id=v7ai5Mz9TZQC&pg=PA4|url-status=live}}</ref><ref name="SartorelliJohns2013">{{cite book | vauthors = Sartorelli AC, Johns DG |title=Antineoplastic and Immunosuppressive Agents|url=https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA104|date=27 November 2013|publisher=Springer Science & Business Media|isbn=978-3-642-65806-8|pages=104–}}</ref>
	The positive and negative ]s of the ] involve ovarian estradiol as the link to the hypothalamic-pituitary system to regulate ]s.
			Estradiol, the most potent of the three major estrogens, was the last of the three to be identified.<ref name="LauritzenStudd2005" /><ref name="FritzSperoff2012" /> It was discovered by Schwenk and Hildebrant in 1933, who ] it via ] of estrone.<ref name="LauritzenStudd2005" /> Estradiol was subsequently isolated and purified from sow ovaries by Doisy in 1935, with its ] determined simultaneously,<ref name="ShoupeHaseltine2012">{{cite book | vauthors = Shoupe D, Haseltine FP |title=Contraception|url=https://books.google.com/books?id=cpDhBwAAQBAJ&pg=PA2|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-2730-4|pages=2–}}</ref> and was referred to variously as ''dihydrotheelin'', ''dihydrofolliculin'', ''dihydrofollicular hormone'', and ''dihydroxyestrin''.<ref name="LauritzenStudd2005" /><ref name="MacCorquodaleThayer1935">{{cite journal | vauthors = MacCorquodale DW, Thayer SA, Doisy EA |title=The Crystalline Ovarian Follicular Hormone|journal=Experimental Biology and Medicine|volume=32|issue=7|year=1935|pages=1182|issn=1535-3702|doi=10.3181/00379727-32-8020P|s2cid=83557813}}</ref><ref name="EPA1981">{{cite book|title=Chemicals Identified in Human Biological Media: A Data Base|url=https://books.google.com/books?id=Gr-0CeNE0Z8C&pg=PA114|year=1981|publisher=Design and Development Branch, Survey and Analysis Division, Office of Program Integration and Information, Office of Pesticides and Toxic Substances, Environmental Protection Agency|pages=114–}}</ref> In 1935, the name ''estradiol'' and the term ''estrogen'' were formally established by the Sex Hormone Committee of the Health Organization of the ]; this followed the names estrone (which was initially called theelin, progynon, folliculin, and ketohydroxyestrin) and estriol (initially called theelol and trihydroxyestrin) having been established in 1932 at the first meeting of the International Conference on the Standardization of Sex Hormones in ].<ref name="FritzSperoff2012" /><ref name="Fausto-Sterling2000">{{cite book| vauthors = Fausto-Sterling A |title=Sexing the Body: Gender Politics and the Construction of Sexuality|url=https://archive.org/details/isbn_9780465077137|url-access=registration|year=2000|publisher=Basic Books|isbn=978-0-465-07714-4|pages=–}}</ref> Following its discovery, a ] of estradiol from ] was developed by Inhoffen and Hohlweg in 1940, and a ] was developed by Anner and Miescher in 1948.<ref name="LauritzenStudd2005"/>
	Estrogen is considered to play a significant role in women’s mental health, with links suggested between the hormone level, mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored.<ref>{{cite journal |author=Douma SL, Husband C, O'Donnell ME, Barwin BN, Woodend AK |title=Estrogen-related mood disorders: reproductive life cycle factors |journal=ANS Adv Nurs Sci |volume=28 |issue=4 |pages=364–75 |year=2005 |pmid=16292022 }}</ref><ref>{{cite journal |author=Lasiuk GC, Hegadoren KM |title=The effects of estradiol on central serotonergic systems and its relationship to mood in women |journal=Biol Res Nurs |volume=9 |issue=2 |pages=147–60 |year=2007 |month=October |pmid=17909167 |doi=10.1177/1099800407305600 }}</ref>
	===Blood vessels===		==Society and culture==
	Estrogen affects certain blood vessels. Improvement in arterial blood flow has been demonstrated in ].<ref>{{cite journal | last1 = Collins | first1 = P | last2 = Rosano | first2 = GM | last3 = Sarrel | first3 = PM | last4 = Ulrich | first4 = L | last5 = Adamopoulos | first5 = S | last6 = Beale | first6 = CM | last7 = McNeill | first7 = JG | last8 = Poole-Wilson | first8 = PA | title = 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease | journal = Circulation | volume = 92 | issue = 1 | pages = 24–30 | year = 1995 | pmid = 7788912 }}</ref>
	===Oncogene===		===Etymology===
			The name ''estradiol'' derives from ''{{not a typo|estra-}}'', ] ''{{lang|grc|οἶστρος}}'' ({{transl|grc|oistros}}, literally meaning "verve or inspiration"),<ref>{{cite web|url=https://www.perseus.tufts.edu/hopper/morph?l=oistros&la=greek|title=Greek Word Study Tool: oistros|publisher=]|access-date=28 December 2011|archive-date=17 March 2012|archive-url=https://web.archive.org/web/20120317152123/http://www.perseus.tufts.edu/hopper/morph?l=oistros&la=greek|url-status=live}}</ref> which refers to the ] ] ] system, and ''{{not a typo|-diol}}'', a chemical term and suffix indicating that the compound is a type of ] bearing two ] ]s.
	Estrogen is suspected to activate certain ], as it supports certain cancers, notably ] and cancer of the ]. In addition, several benign gynecologic conditions are dependent on estrogen, such as ], ]ta uteri, and uterine bleeding.
	===Pregnancy===		== References ==
			{{reflist|refs=
	The effect of estradiol, together with ] and ], in ] is less clear. They may promote uterine blood flow, myometrial growth, stimulate breast growth and at term, promote cervical softening and expression of myometrial ] receptors.
			<ref name=":0">{{cite web |url=https://medlineplus.gov/ency/article/003711.htm |title=Estradiol blood test: MedlinePlus Medical Encyclopedia |website=medlineplus.gov |language=en |access-date=2019-05-06 |archive-date=18 March 2021 |archive-url=https://web.archive.org/web/20210318225130/https://medlineplus.gov/ency/article/003711.htm |url-status=live }}</ref>
	==Role in sex differentiation of the brain==
	One of the fascinating twists to mammalian sex differentiation is that estradiol is one of the two active ]s of testosterone in males (the other being ]), and since fetuses of both sexes are exposed to similarly high levels of maternal estradiol, this source cannot have a significant impact on prenatal sex differentiation. Estradiol cannot be transferred readily from the circulation into the brain, whereas testosterone can; thus sex differentiation can be caused by the testosterone in the brain of most male mammals, including humans, aromatizing in significant amounts into estradiol. There is also now evidence the programming of adult male sexual behavior in animals is largely dependent on estradiol produced in the central nervous system during prenatal life and early infancy from testosterone.<ref>{{cite journal | last = Harding | first = Prof. Cheryl F. | title = Hormonal Modulation of Singing: Hormonal Modulation of the Songbird Brain and Singing Behavior | journal = Ann. N.Y. Acad. Sci. | volume = 1016 | pages = 524–539 | publisher = The New York Academy of Sciences | month = June | year = 2004 | url = http://www.annalsnyas.org/content/vol1016/issue1/index.dtl | doi = 10.1196/annals.1298.030 | accessdate = 2007-03-07 | pmid = 15313793}}</ref> However, it is not yet known whether this process plays a minimal or significant part in human sexual behaviors although evidence from other mammals tends to indicate that it does.<ref>{{cite journal | last = Simerly | first = Richard B. | title = Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain | journal = Annual Rev. Neurosci. | volume = 25 | pages =507–536 | date = 2002-03-27 | url = http://www.healthsystem.virginia.edu/internet/neuroscience/BehavioralNeuroscience/Simerley-EFR-1-4.pdf | doi = 10.1146/annurev.neuro.25.112701.142745 | pmid = 12052919 | format = pdf | accessdate = 2007-03-07}}</ref>
			<ref name=Abbott2009>{{cite web |title=Estradiol |url=https://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf |website=ilexmedical.com |access-date=4 July 2024 |archive-date=4 February 2024 |archive-url=https://web.archive.org/web/20240204065541/https://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf |url-status=live }}</ref>
	Recently, the volumes of ] brain structures in phenotypical males were found to change to approximate those of typical female brain structures when exposed to estradiol over a period of months.<ref name="eje-utrecht">{{cite journal| author = Hulshoff, Cohen-Kettenis et al. | year = 2006 | month = July | title = Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure | url = http://www.eje-online.org/cgi/content/abstract/155/suppl_1/S107 | journal = European Journal of Endocrinology | issue = 155 | pages = 107–114 | doi = 10.1530/eje.1.02248 | volume = 155}}</ref> This would suggest estradiol has a significant part to play in sex differentiation of the brain, both prenatally and throughout life.
			<ref name="BajajBerman2011">{{cite book |author1=Lalit Bajaj |author2=Stephen Berman |title=Berman's Pediatric Decision Making |url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160 |date=1 January 2011 |publisher=Elsevier Health Sciences |isbn=978-0-323-05405-8 |pages=160– |access-date=22 August 2023 |archive-date=11 January 2023 |archive-url=https://web.archive.org/web/20230111143033/https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160 |url-status=live }}</ref>
	==Estradiol medication==
	Estrogen is marketed in a number of ways to address issues of ]. Thus, there are oral, transdermal, topical, injectable, and vaginal preparations. Furthermore, the estradiol molecule may be linked to an ] group at C17 (sometimes also at C3) position to facilitate the administration. Such modifications give rise to '''estradiol acetate''' (oral and vaginal applications) and to '''estradiol cypionate''' (injectable).
			<ref name="CraigStitzel2004">{{cite book |vauthors=Craig CR, Stitzel RE |title=Modern Pharmacology with Clinical Applications |url=https://books.google.com/books?id=KqA29hQ-m3AC&pg=PA706 |year=2004 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-3762-3 |pages=706–}}</ref>
	Oral preparations are not necessarily predictably absorbed, and are subject to a first pass through the liver, where they can be metabolized, and also initiate unwanted side effects. Therefore, alternative routes of administration that bypass the liver before primary target organs are hit have been developed. Transdermal and transvaginal routes are not subject to the initial liver passage.
			<ref name="FalconeHurd2007">{{cite book |vauthors=Falcone T, Hurd WW |title=Clinical Reproductive Medicine and Surgery |url=https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA22 |year=2007 |publisher=Elsevier Health Sciences |isbn=978-0-323-03309-1 |pages=22– |access-date=22 October 2016 |archive-date=10 January 2023 |archive-url=https://web.archive.org/web/20230110014156/https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA22 |url-status=live }}</ref>
	], the most common estrogen ingredient in ]s, is a more profound alteration of the estradiol structure.
			<ref name="FordRoach2013">{{cite book |vauthors=Ford SR, Roach SS |title=Roach's Introductory Clinical Pharmacology |url=https://books.google.com/books?id=LwOaAgAAQBAJ&pg=PA525 |date=7 October 2013 |publisher=Lippincott Williams & Wilkins |isbn=978-1-4698-3214-2 |pages=525–}}</ref>
	==Therapy==
	]) 20 mg]]
	]) 1 mg]]
	{{also|Estrogen patch}}
			<ref name="HochadelMosby2015">{{cite book |vauthors=Hochadel M |title=Mosby's Drug Reference for Health Professions |url=https://books.google.com/books?id=IuF1BwAAQBAJ&pg=PA602 |date=1 April 2015 |publisher=Elsevier Health Sciences |isbn=978-0-323-31103-8 |pages=602–}}</ref>
	===Blocking estrogens===
	Inducing a state of ] may be beneficial in certain situations where estrogens are contributing to unwanted effects, e.g., certain forms of ], ], and premature ]. Estrogen levels can be reduced by inhibiting production using ]-releasing factor ] (]s) or blocking the ] ] using an ], such as ], or with an ] ], such as ]. ] is known to reduce estradiol.<ref>{{cite book | first=Andrew | last= Chevallier | year= 2000 | title=Encyclopedia of Herbal Medicine: The Definitive Home Reference Guide to 550 Key Herbs with all their Uses as Remedies for Common Ailments | editor=Gillian Emerson-Roberts | publisher= DK Publishing | isbn=0-7894-6783-6 }}</ref>
			<ref name="Kuhl2003">{{cite journal |vauthors=Kuhl H |title=Östrogene für den Mann? |trans-title=Estrogens for the man? |journal=Blickpunkt der Mann |year=2003 |volume=1 |issue=3 |pages=6–12 |issn=1727-0669 |url=https://www.kup.at/journals/summary/3583.html |access-date=22 August 2023 |archive-date=22 August 2023 |archive-url=https://web.archive.org/web/20230822235745/https://www.kup.at/journals/summary/3583.html |url-status=live }}</ref>
	===Hormonal contraception===
	A derivative form of estradiol, ethinylestradiol, is a major component of hormonal contraceptive devices. Combined forms of ] contain ethinylestradiol and a ], which both contribute to the inhibition of ], ], and ], which accounts for the ability of these ] methods to prevent ovulation and thus prevent pregnancy. Other types of hormonal birth control contain only ] and no ethinylestradiol.
			<ref name="McMillanFeigin2006">{{cite book |vauthors=McMillan JA, Feigin RD, DeAngelis C, Jones MD |title=Oski's Pediatrics: Principles & Practice |url=https://books.google.com/books?id=VbjFQiz8aR0C&pg=PA550 |year=2006 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-3894-1 |pages=550–}}</ref>
	===List of estradiol medications===
	====Products====
	* Oral versions: estradiol acetate (Estrace), estradiol valerate (Estrofem)
	* Transdermal preparation: Alora, Climara, Vivelle-Dot, Menostar, Estraderm TTS, Estraderm MX, EvaMist
	* Ointments: Divigel, Estrasorb Topical, Estrogel, Elestrin
	* Injection: estradiol cypionate, estradiol valerate
	* Vaginal ointment: Estrace Vaginal Cream
	* ]: Estring (estradiol acetate), Femring
	* Estradiol combined with a progestin: ], AngeliQ, Cyclo-Progynova
			<ref name="Mechoulam_2005">{{cite journal |vauthors=Mechoulam R, Brueggemeier RW, Denlinger DL |title=Estrogens in insects |journal=Cellular and Molecular Life Sciences |date=September 1984 |volume=40 |issue=9 |pages=942–944 |doi=10.1007/BF01946450 |s2cid=31950471}}</ref>
	===Hormone replacement therapy===
	If severe side effects of low levels of estradiol in a woman's blood are experienced (commonly at the beginning of ] or after ]), ] may be prescribed. Often such therapy is combined with a ].
			<ref name="NauntonAl Hadithy2006">{{cite journal |vauthors=Naunton M, Al Hadithy AF, Brouwers JR, Archer DF |title=Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women |journal=Menopause |volume=13 |issue=3 |pages=517–27 |year=2006 |pmid=16735950 |doi=10.1097/01.gme.0000191881.52175.8c |s2cid=42748448}}</ref>
	Estrogen therapy may be used in treatment of ] in women when there is a need to develop sperm-friendly ] mucus or an appropriate uterine lining. This is often prescribed in combination with ].
			<ref name="Ozon_1972">{{cite book |editor=Idler DR |title=Steroids In Nonmammalian Vertebrates |date=1972 |publisher=Elsevier Science |location=Oxford |isbn=978-0323140980 |vauthors=Ozon R |chapter=Estrogens in Fishes, Amphibians, Reptiles, and Birds |pages=390–414 |chapter-url=https://books.google.com/books?id=Ei46GE-lj2wC&q=estradiol%20vertebrates&pg=PA393 |access-date=17 October 2020 |archive-date=10 January 2023 |archive-url=https://web.archive.org/web/20230110014156/https://books.google.com/books?id=Ei46GE-lj2wC&q=estradiol%20vertebrates&pg=PA393 |url-status=live }}</ref>
	Estrogen therapy can also be used to treat advanced prostate cancer, as well as to relieve symptoms of breast cancer.<ref>{{cite journal |author=Ockrim JL, Lalani el-N, Kakkar AK, Abel PD |title=Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism |journal=J. Urol. |volume=174 |issue=2 |pages=527–33; discussion 532–3 |year=2005 |month=August |pmid=16006886 |url=http://linkinghub.elsevier.com/retrieve/pii/00005392-200508000-00036 |doi=10.1097/01.ju.0000165567.99142.1f}}</ref><ref>{{cite journal |author=Carruba G, Pfeffer U, Fecarotta E, ''et al.'' |title=Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells |journal=Cancer Res. |volume=54 |issue=5 |pages=1190–3 |year=1994 |month=March |pmid=8118804 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=8118804}}</ref>
			<ref name="pmid7083198">{{cite journal |vauthors=Ryan KJ |title=Biochemistry of aromatase: significance to female reproductive physiology |journal=Cancer Research |volume=42 |issue=8 Suppl |pages=3342s–3344s |date=August 1982 |pmid=7083198}}</ref>
	Estrogen therapy is also used to maintain female hormone levels in ] women.
			<ref name="Preedy2011">{{cite book |vauthors=Preedy VR |title=Handbook of Growth and Growth Monitoring in Health and Disease |url=https://books.google.com/books?id=9FQXunlUvz0C&pg=PA2661 |date=2 December 2011 |publisher=Springer Science & Business Media |isbn=978-1-4419-1794-2 |pages=2661– |access-date=9 June 2017 |archive-date=10 January 2023 |archive-url=https://web.archive.org/web/20230110014156/https://books.google.com/books?id=9FQXunlUvz0C&pg=PA2661 |url-status=live }}</ref>
	====Notes====
	Not all products are available worldwide. Estradiol is also part of conjugated estrogen preparations, such as ], though it is not the major ingredient (Premarin consists of hundreds of estrogen derivatives. As the name indicates, it comes from ] ]s' ].)
			<ref name="PriceBlauer1997">{{cite journal |vauthors=Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW |title=Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol |journal=Obstetrics and Gynecology |volume=89 |issue=3 |pages=340–5 |date=March 1997 |pmid=9052581 |doi=10.1016/S0029-7844(96)00513-3 |s2cid=71641652}}</ref>
	==Adverse effects==
	Adverse effects, which may occur as a result of use of estradiol and have been associated with estrogen and/or progestin therapy, include changes in ], ], increase in size of ], ] including ], changes in cervical secretion and ], ], ], ], ], ], fibrocystic breast changes and ]. Cardiovascular effects include chest pain, deep and superficial ], ], ], ], ], and increased ]. Gastrointestinal effects include ] and vomiting, abdominal cramps, ], ], ], ], ], ] ], increased incidence of ], ], or enlargement of ] ]. Skin adverse effects include ] or ] that may continue despite discontinuation of the drug. Other effects on the skin include ], ], ], ] eruption, loss of scalp hair, ], ], or ]. Adverse effects on the eyes include ] ] ], steepening of ] curvature or intolerance to ]. Adverse ] effects include headache, ], ], mental depression, ], ]/], ], ], and worsening of ]. Other adverse effects include changes in weight, reduced ] tolerance, worsening of ], ], ], ], ], ], changes in ], ], ], ], syncope, toothache, tooth disorder, ], ], exacerbation of ], and increased ].<ref name=etetusp>{{cite web | url=http://www.wcrx.com/pdfs/pi/pi_estrace_wc_imprint.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Barr Laboratories, Inc. | authorlink=Barr Laboratories | month=March | year=2008 | publisher=wcrx.com | format=PDF | accessdate=27 January 2010 }}</ref><ref>{{cite web |url=http://media.pfizer.com/files/products/uspi_estring.pdf |title=ESTRING (estradiol vaginal ring) |author=Pfizer |month=August |year=2008 |format=PDF }}</ref>
			<ref name="StanczykArcher2013">{{cite journal |vauthors=Stanczyk FZ, Archer DF, Bhavnani BR |title=Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment |journal=Contraception |volume=87 |issue=6 |pages=706–27 |date=June 2013 |pmid=23375353 |doi=10.1016/j.contraception.2012.12.011}}</ref>
	Estrogen combined with medroxyprogesterone is associated with an increased risk of ]. It is not known whether estradiol taken alone is associated with an increased risk of dementia. Estrogens should only be used for the shortest possible time and at the lowest effective dose due to these risks. Attempts to gradually reduce the medication via a dose taper should be made every three to six months.<ref name=etetusp/>
			}}
	===Mechanism of action on cancer cell proliferation===
	Estradiol has been tied to the development and progression of cancers such as breast cancer, ovarian cancer and endometrial cancer. Estradiol effects target tissues by interacting with two nuclear hormone receptors called ] α (ERα) and estrogen receptor β (ERβ). <ref name=flav>{{cite journal|last=Bulzomi|first=Pamela|coauthors=Bolli A., Galluzzo P., Leone S., Acconcia F., Marino M.|title=Naringenin and 17β-estradiol coadministration prevents hormone-induced human cancer cell growth|journal=IUBMD Life|year=2010|month=January|volume=62|issue=1|pages=51-60|doi=10.1002/iub.279|url=http://onlinelibrary.wiley.com/doi/10.1002/iub.279/full|accessdate=26 March 2012}}</ref><ref name=pome>{{cite journal|last=Sreeja|first=Sreekumar|coauthors=Kumar T., Lakshmi B., Sreeja S.|title=Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation|journal=Journal of Nutritional Biochemistry|date=17|year=2011|month=March|doi=10.1016/j.jnutbio.2011.03.015|url=http://www.jnutbio.com/article/S0955-2863(11)00112-4/abstract|accessdate=26 March 2012}}</ref> One of the functions of these estrogen receptors is ]. Once the ] binds to the estrogen receptors, the hormone-receptor complexes then bind to specific ], possibly causing damage to the DNA and an increase in cell division and DNA replication. Eukaryotic cells respond to damaged DNA by stimulating or impairing G1, S, or G2 phases of the cell cycle to initiate DNA repair. As a result, cellular transformation and cancer cell proliferation occurs. <ref name=estrogen>{{cite journal|last=Thomas|first=Christoforos|coauthors=Strom A., Lindberg K., Gustafsson J.|title=Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling|journal=Breast Cancer Research and Treatment|date=22|year=2010|month=June|volume=127|issue=2|pages=417-427|doi=10.1007/s10549-010-1011-z|url=http://www.springerlink.com/content/12v770887k8150k4/|accessdate=26 March 2012}}</ref>
	====Suppressing the estrogenic effects of estradiol====
	In order to prevent and treat estrogen-dependent cancers, estrogen activity must be blocked in the affected tissues without compromising its beneficial effects, such as female and male reproduction, on unaffected tissues. Estrogen receptor α (ERα) was found to promote proliferation of cancer cells whereas estrogen receptor β (ERβ) acts as a tumor suppressor. <ref name=pome></ref> Researchers have experimented by exposing ] cervical cancer cells to ] and ] to explore their effects on ERβ to encourage it’s anti-estrogenic effect or to discourage ERα estrogenic effects. <ref name=flav></ref><ref name=pome></ref>
	In one study, a flavonoid called ] was used for its disease preventing component. Researchers used HeLa cervical cancer cells and ] liver cancer cell lines. <ref name=flav></ref> The researchers used ''in'' ''vivo'' and ''in vitro'' exposure of the cancer cells to estradiol to explore the impairment effects of flavonoids on estradiol. When naringenin was introduced to these cancer cells, estradiol and naringenin compete to bind to ERα, with the preference being the flavonone. As the concentration of naringenin increases, the molar fraction of estradiol binding to ERα decreases, thus reducing its estrogenic effect of cancer cell proliferation and inducing pro], or programmed cell death. Naringenin was found to bind to ERβ with up to five times higher affinity when compared to ERα, therefore increasing the anti-estrogenic effect of ERβ. <ref name=flav></ref>
	In another study, ] extract was used for its ] properties. HeLa cervical cancer cells and SKOV3 ovarian ] were experimented upon. These cancer cells were treated with different concentrations of pomegranate extract, referred to as PME, to investigate whether pomegranate extract effects cancer cells. <ref name=pome></ref> At low concentrations, pomegranate extract showed no stimulation, but at higher concentrations, PME showed a growth inhibitory effect on the cancer cells. Pomegranate extract binds to estrogen receptors, namely ERα, in a concentration-dependent manner and inhibited the binding of estradiol. This encouraged the antiproliferative activity of cancer cells and suppressed growth of the malignant cells. <ref name=pome></ref> Although pomegranate extract suppressed the growth of cancer cells, the study did not mention whether or not pomegranate extract exposure to existing cancer cells induced apoptosis or necrosis.
	====Prospective research====
	Although naringenin and other flavonoids and antioxidants could be acquired by eating foods rich in those components or by taking ], the ability of an individual to absorb and metabolize these food nutrients varies from person to person. <ref name=flav></ref> Researchers suggest that the complex role of flavonoids and plant extracts should be studied further before including them in specific nutritional recommendations. <ref name=flav></ref> <ref name=pome></ref> However, the studies do suggest that regular consumption of naringenin may slow the rate that estradiol-dependent cancer proliferate and naringenin is an exceptional option as a chemopreventive agent in estradiol-dependent cancers. Since pomegranate extract is an ERα antagonist, researchers propose that pomegranate extract is a promising alternative in breast cancer therapy and may be a preventative of estrogen-dependent ]s. <ref name=pome></ref> Researchers also propose that the increase tumor suppression due to the presence of ERβ may result in a more successful response to ] treatments.<ref name=estrogen></ref>
	== Interactions ==
	], ], ] and ] decrease the levels of estrogens, such as estradiol, by speeding up its metabolism, whereas ], ], ], ], ] and ] may slow down metabolism, leading to increased levels in the blood plasma.<ref name=etetusp/>
	==Contraindications==
	Estradiol should be avoided when there is undiagnosed abnormal genital bleeding, known, suspected or a history of ], current treatment for metastatic disease, known or suspected estrogen-dependent ], ], pulmonary embolism or history of these conditions, active or recent arterial thromboembolic disease such as stroke, myocardial infarction, liver dysfunction or disease. Estradiol should not be taken by people with a ]/allergy or those who are pregnant or are suspected pregnancy.<ref name=etetusp/>
	==See also==
	*]
	*]
	*]
	*]
	*], the family of plant chemicals which can act on estradiol receptive tissue in mammals, although the exact mechanism at hand is unclear.
	==References==
	{{Reflist}}
	==Additional images==
	<gallery>
	File:Steroidogenesis.svg|]
	</gallery>
			{{Template:Estradiol salts}}
			{{Estradiol}}
	{{Hormones}}		{{Hormones}}
	{{Sex hormones}}		{{Endogenous steroids}}
			{{Estrogen receptor modulators}}
	{{Cholesterol and steroid intermediates}}
			{{Portal bar | Medicine}}
			{{Authority control}}
			]
			]
			]
			]
			]
			]
	]		]
	]		]
	]		]
	]		]
			]
	]
			]
			]
	]
			]
	]
			]
	]
			]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]
	]